RhumbLine Advisers’s Clearside Biomedical CLSD Stock Holding History

RhumbLine Advisers’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-73	Closed	-$1.42K	–	4224
2024 Q2	$1.42K	Hold	73	–	–	﹤0.01%	4212
2024 Q1	$1.67K	Hold	73	–	–	﹤0.01%	4102
2023 Q4	$1.28K	Hold	73	–	–	﹤0.01%	4134
2023 Q3	$950	Hold	73	–	–	﹤0.01%	4185
2023 Q2	$1.22K	Buy	+73	New	+$1.26K	﹤0.01%	4270
2019 Q2	–	Sell	-2,421	Closed	-$50K	–	2973
2019 Q1	$50K	Sell	2,421 -44	-2%	-$873	﹤0.01%	2919
2018 Q4	$40K	Buy	2,465 +805	+48%	+$37.8K	﹤0.01%	2955
2018 Q3	$153K	Sell	1,660 -120	-7%	-$14.3K	﹤0.01%	2799
2018 Q2	$285K	Buy	1,780 +537	+43%	+$90.5K	﹤0.01%	2558
2018 Q1	$200K	Buy	1,243 +66	+6%	+$8.04K	﹤0.01%	2604
2017 Q4	$124K	Sell	1,177 -278	-19%	-$29.8K	﹤0.01%	2745
2017 Q3	$191K	Buy	1,455 +7	+0.5%	+$855	﹤0.01%	2752
2017 Q2	$198K	Buy	+1,448	New	+$174K	﹤0.01%	2763

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGH

GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

RhumbLine Advisers's CLSD Position: Q3 2024 in Review

RhumbLine Advisers sold out of Clearside Biomedical (CLSD) in Q3 2024, closing a stake of 73 shares — an estimated $1.42K sold.

RhumbLine Advisers first reported a position in CLSD in Q2 2017 and held it in 13 quarters. The position peaked at $285K in Q2 2018. 48 funds tracked by Wall St. Rank hold CLSD as of Q3 2024.

RhumbLine Advisers reported no remaining Clearside Biomedical position as of Q3 2024 after selling out during the quarter.
RhumbLine Advisers sold 73 Clearside Biomedical shares in Q3 2024, an estimated $1.42K.
RhumbLine Advisers first reported a position in Clearside Biomedical in Q2 2017 and held it in 13 quarters.
RhumbLine Advisers's Clearside Biomedical position peaked at $285K in Q2 2018.
48 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.